Market Access Views & Analysis

Views & Analysis

Market Access

NICE and orphan drug recommendations: Should we be more worr...

Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.

Market Access

Nine for 2024, Pt 1: From fragility to resilience

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic.

R&D

Threats impacting the pharmaceutical industry in 2024

As we approach 2024, what will the next 12 months have in store for pharma?

Market Access

NCVR: What's the true price of negotiation?

A country’s ability to open trials quickly is a key consideration for commercial sponsors planning programmes of research globally.

Market Access

A strategic approach to local affiliates in the global era

While global harmonisation remains the holy grail, the reality is that pharmaceutical companies still face significant challenges navigating regulatory differences.

Market Access

What the FDA’s groundbreaking guidance really means for psyc...

Mental health care is fraught with treatment-resistant conditions and ineffective or side-effect-ridden therapies.1 Psychedelic therapy, once relegated to the fringes of medical

NICE and orphan drug recommendations: Should we be more worr...

Nine for 2024, Pt 1: From fragility to resilience

Threats impacting the pharmaceutical industry in 2024

NCVR: What's the true price of negotiation?

A strategic approach to local affiliates in the global era

What the FDA’s groundbreaking guidance really means for psyc...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks